Maxim Pharmaceuticals Inc.
Division of Immune Pharmaceuticals Inc.
www.maxim.com
Latest From Maxim Pharmaceuticals Inc.
Germany's Growth Story
Germany's biotech investment has propelled a handful of companies onto the public markets a lot sooner than their US or UK counterparts. These German companies have followed aggressive acquisition strategies, most often buying into the US, sometimes using newly-minted Neuer Markt paper. Some are seeking through these acquisitions to both broaden their technology platform and acquire a product portfolio, hoping thereby to avoid the pitfalls of a narrow focus. It's too early to tell whether such a dual model will work. But the fact that Germany's young companies are finding their own approach to competing globally shows that the country's biotech initiative has already had some success.
GPC Leads German Dealmaking
Germany's GPC Biotech AG has already signed two deals with pharmaceutical companies this year. Both partners are fellow Germans, but neither deal would have happened had GPC not chosen to make itself international through acquiring privately held US oncology company Mitotix Inc. last March.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Hepatic (Liver)
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Immune Pharmaceuticals Inc.
- Senior Management
-
Larry G Stambaugh, Chmn., Pres. & CEO
John Prunty, VP, Fin. & CFO
Ben Tseng, PhD, VP, Research - Contact Info
-
Maxim Pharmaceuticals Inc.
Phone: (858) 453-4040
8899 University Center Ln.
Ste. 400
San Diego, CA 92122
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Maxim Pharmaceuticals Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice